Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma

被引:5
|
作者
Trape, Jaume [1 ]
Montesinos, Jesus [2 ]
Franquesa, Josefina [1 ]
Sala, Maria [1 ]
Figols, Cristina [1 ]
Miguel, Ana [2 ]
Domenech, Montserrat [2 ]
机构
[1] Althaia Xarxa Assistencial Manresa, Serv Clin Chem, Dept Biol Diag, Manresa 08243, Catalonia, Spain
[2] Althaia Xarxa Assistencial Manresa, Serv Oncol, Manresa 08243, Catalonia, Spain
关键词
analytical goals; biological variation; LDH; reference change value; S100; SERUM CONSTITUENTS; LONG-TERM; CANCER;
D O I
10.1515/CCLM.2012.799
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Biological variation is important for determining analytical goals and for establishing the magnitude of change between two consecutive measurements. The aim of this study was to determine the biological variation for S100 beta and lactate dehydrogenase in patients diagnosed with malignant melanoma but without evidence of disease recurrence. Methods: The biological variation of S100 beta and lactate dehydrogenase was estimated from a mean of four consecutive measurements in 32 patients diagnosed with malignant melanoma but without evidence of disease recurrence, 3 months after tumor resection or 4 months after finishing adjuvant treatment. The mean sampling interval was 3 months. Results: Mean concentrations of S100 beta and lactate dehydrogenase were 0.0557 mu g/L and 6.3 mu kat/L, respectively. Between-run analytical variation was 3.5% at 0.181 mu g/L for S100 beta and 3.5% at 2.83 mu kat/L for lactate dehydrogenase. Biological variations obtained for S100 beta and lactate dehydrogenase were 14.2% and 8.2%, respectively. The analytical goals (defined as 50% of biological variation) were 7.1% for S100 beta and 4.1% for lactate dehydrogenase. Conclusions: The estimation of biological variation allows us to calculate analytical goals and reference change values. These are necessary tools for the correct interpretation of serial measurements in patient follow-up.
引用
收藏
页码:927 / 929
页数:3
相关论文
共 50 条
  • [31] Multicenter evaluation of the analytical and clinical performance of the Elecsys® S100 immunoassay in patients with malignant melanoma
    Alber, B
    Hein, R
    Garbe, C
    Caroli, U
    Luppa, PB
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (05) : 557 - 563
  • [32] S100β is a more reliable tumor marker in peripheral flood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase
    Krähn, G
    Kaskel, P
    Sander, S
    Waizenhöfer, JPY
    Wortmann, S
    Leiter, U
    Peter, RU
    ANTICANCER RESEARCH, 2001, 21 (2B) : 1311 - 1316
  • [33] The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
    McClay, EF
    McClay, MET
    Monroe, L
    Baron, PL
    Cole, DJ
    O'Brien, PH
    Metcalf, JS
    Maize, JC
    BRITISH JOURNAL OF CANCER, 2000, 83 (01) : 16 - 21
  • [34] The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma
    McClay E.F.
    McClay M.E.T.
    Monroe L.
    Baron P.L.
    Cole D.J.
    O'Brien P.H.
    Metcalf J.S.
    Maize J.C.
    British Journal of Cancer, 2000, 83 (1) : 16 - 21
  • [35] Serum S100 - A marker for disease monitoring in metastatic melanoma
    Dummer, R
    JollerJemelka, HI
    Boni, R
    Burg, G
    DERMATOLOGY, 1997, 194 (03) : 208 - 212
  • [36] Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    B Weide
    M Elsässer
    P Büttner
    A Pflugfelder
    U Leiter
    T K Eigentler
    J Bauer
    M Witte
    F Meier
    C Garbe
    British Journal of Cancer, 2012, 107 : 422 - 428
  • [37] Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis
    Weide, B.
    Elsaesser, M.
    Buettner, P.
    Pflugfelder, A.
    Leiter, U.
    Eigentler, T. K.
    Bauer, J.
    Witte, M.
    Meier, F.
    Garbe, C.
    BRITISH JOURNAL OF CANCER, 2012, 107 (03) : 422 - 428
  • [38] Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma
    Tas, F
    Yasasever, V
    Duranyildiz, D
    Camlica, H
    Ustuner, Z
    Aydiner, A
    Topuz, E
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 225 - 228
  • [39] Ultraviolet B exposure could influence the interpretation of serum S100β levels in patients with malignant melanoma
    Vitzthum, J.
    Doerr, H. D.
    Meineke, V.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (04) : 772 - 773
  • [40] CLINICAL-SIGNIFICANCE OF SERUM S100 IN METASTATIC MALIGNANT-MELANOMA
    GUO, HB
    STOFFELWAGNER, B
    BIERWIRTH, T
    MEZGER, J
    KLINGMULLER, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (06) : 924 - 928